NewAmsterdam Pharma Company (NasdaqGM:NAMS) 2026 Conference Transcript

Summary of NewAmsterdam Pharma Conference Call Company Overview - Company: NewAmsterdam Pharma (NasdaqGM: NAMS) - Event: 2026 Emerging Outlook Biotech Summit - Date: February 11, 2026 Key Points Industry and Product Focus - NewAmsterdam Pharma is focused on the development of obicetrapib, a CETP inhibitor aimed at treating hyperlipidemia and associated cardiovascular risks [1][2] Clinical Trials and Study Updates - PREVAIL Study: Expected mid-year update on the study's readout timelines, with a commitment to provide updates based on event adjudication over two years [7][8] - BROADWAY Study: Demonstrated a 21% MACE (Major Adverse Cardiac Events) benefit, with event rates tracking in line with PREVAIL [7][8] - Compliance Tracking: Emphasis on patient compliance due to the long duration of outcome studies, with strategies in place to maintain patient engagement [16][17] Drug Efficacy and Safety - Obicetrapib shows the ability to achieve risk-based goals in 70%-80% of patients, with a convenient dosing regimen of a 10-mg oral pill [22] - The drug has demonstrated a reduction in Lp(a) levels by upwards of 50% and has potential implications for diabetes and Alzheimer's disease [23][52] - The safety profile is favorable, with lower adverse events compared to placebo, enhancing patient retention in studies [17][18] Market Opportunity - There are approximately 30 million patients in the U.S. not achieving risk-based goals despite being on treatment for hyperlipidemia, indicating a significant market opportunity [24][52] - The commercial landscape is expected to evolve positively, with NewAmsterdam positioned to leverage its differentiated drug profile against competitors [51][72] Competitive Landscape - NewAmsterdam is the only company with a CETP inhibitor in development, with expectations for regulatory approval in Europe and the U.S. [51][76] - The company plans to differentiate obicetrapib by emphasizing its broader benefits beyond LDL-C reduction, targeting various patient populations including those with diabetes and elevated Lp(a) levels [52][76] Regulatory and Launch Strategy - The U.S. filing is contingent on having outcomes data available at launch, while the European filing has already occurred [76] - The company is confident in its ability to launch successfully, drawing on the experience of its commercial team [70][72] Future Studies and Insights - Ongoing studies (VINCENT, RUBENS, REMBRANDT) will further explore the drug's efficacy, particularly regarding small LDL particle elimination [31][34] - The HORIZON study will provide insights into the contribution of Lp(a) to MACE benefits observed in BROADWAY, which may inform expectations for PREVAIL [79] Additional Insights - The design of the PREVAIL study is intended to avoid the pitfalls of previous CETP inhibitors, focusing on LDL reduction rather than HDL elevation [43][44] - The company has a strong leadership team with extensive experience in cardiology and lipidology, which is expected to enhance the study's execution and outcomes [42][43] This summary encapsulates the critical aspects of NewAmsterdam Pharma's conference call, highlighting the company's strategic focus, clinical developments, market opportunities, and competitive positioning within the biotech industry.